Citations - Mirza Mansoor Raza

CONCLUSIONS: PARP inhibitors play a pivotal role in the management of newly diagnosed ovarian cancer, which will affect subsequent treatment choices. Refinement of testing for patient selection and identification of regimens to treat populations that appear to benefit less from PARP inhibitors are a priority.... Read more
Published on: 2020-06-23
Source: Mirza Mansoor Raza
By: M R Mirza
CONCLUSIONS: PARP inhibitors play a pivotal role in the management of newly diagnosed ovarian cancer, which will affect subsequent treatment choices. Refinement of testing for patient selection and identification of regimens to treat populations that appear to benefit less from PARP inhibitors are a priority.... Read more
Published on: 2020-06-23
Source: Mirza Mansoor Raza
By: M R Mirza
CONCLUSIONS: PARP inhibitors play a pivotal role in the management of newly diagnosed ovarian cancer, which will affect subsequent treatment choices. Refinement of testing for patient selection and identification of regimens to treat populations that appear to benefit less from PARP inhibitors are a priority.... Read more
Published on: 2020-06-23
Source: Mirza Mansoor Raza
By: M R Mirza
CONCLUSIONS: PARP inhibitors play a pivotal role in the management of newly diagnosed ovarian cancer, which will affect subsequent treatment choices. Refinement of testing for patient selection and identification of regimens to treat populations that appear to benefit less from PARP inhibitors are a priority.... Read more
Published on: 2020-06-23
Source: Mirza Mansoor Raza
By: M R Mirza
CONCLUSIONS: PARP inhibitors play a pivotal role in the management of newly diagnosed ovarian cancer, which will affect subsequent treatment choices. Refinement of testing for patient selection and identification of regimens to treat populations that appear to benefit less from PARP inhibitors are a priority.... Read more
Published on: 2020-06-23
Source: Mirza Mansoor Raza
By: M R Mirza
CONCLUSIONS: PARP inhibitors play a pivotal role in the management of newly diagnosed ovarian cancer, which will affect subsequent treatment choices. Refinement of testing for patient selection and identification of regimens to treat populations that appear to benefit less from PARP inhibitors are a priority.... Read more
Published on: 2020-06-23
Source: Mirza Mansoor Raza
By: M R Mirza
CONCLUSIONS: PARPi are a valid option for the treatment of both primary and relapsed OC patients, with a relative low incidence of severe side effects.... Read more
Published on: 2020-06-03
Source: Mirza Mansoor Raza
By: Ilary Ruscito
  • Other

    Citations

  • Other

    Citations

Translate »